Baseline characteristics for patients with multiple system atrophy entering a randomized, controlled study of the anti-α-synuclein monoclonal antibody Lu AF82422
Objective: Report baseline characteristics for patients with multiple system atrophy (MSA) entering a study to assess the safety and efficacy of alpha-synuclein (α-syn) monoclonal antibody…Potential role of Alpha-synuclein levels in Platelets in GBA-related PD
Objective: Identification of a blood biomarker to predict PD diagnosis or to monitor the disease progression. Background: Previous evidence suggests differences in systemic alpha-synuclein levels…Transcriptome-microRNA correlation and the regulation of targeted gene expression in de novo Parkinson’s disease patients.
Objective: To conduct a case-control study in single, comprehensive movement disorder center in Seoul. Background: Parkinson’s disease (PD) is the second most common neurodegenerative disease…Proof-of-concept clinical trial: Prevent cognitive decline in GBA-associated Parkinson’s Disease
Objective: To prevent cognitive decline in GBA-associated Parkinson’s Disease (PD). Background: Dementia represents a key milestone in the course of PD with limited effective treatments…Elevated plasma CREG1 levels are linked to a lower risk of Parkinson’s disease
Objective: The purpose of this study is to assess the causal associations between plasma cellular repressor of E1A-stimulated genes 1 (CREG1) levels and the risk…Cerebrospinal fluid biomarkers for diagnosis of Parkinson’s disease: a systematic review and network meta-analysis
Objective: In this study, we intended to use network meta-analysis to compare the diagnostic performances of different CSF biomarkers in the diagnosis and differential diagnosis…A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson’s Disease (PADOVA): Rationale, Design, and Baseline Data
Objective: The study will evaluate the efficacy and safety of prasinezumab in individuals with early-stage Parkinson's disease (PD) on stable symptomatic therapy. Background: Available treatments…Analysis of the network of genes related to Parkinson’s and identification of key proteins
Objective: Parkinson's disease (PD) is one of the increasing age-related diseases with no definite treatment. PD is considered as a disorder with genetic and non-genetic…Neuroprotective effects of oral consumption of Bifidobacterium lactis and Lactobacillus acidophilus probiotics on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropytide-induced Parkinson’s Disease mouse model
Objective: To explore the effects of probiotics strains Bifidobacterium animalis subsp. lactis (B.lactis) and Lactobacillus acidophilus (L.acidophilus) on the inflammation of gut-brain axis and degeneration…Salivary α-synuclein in Parkinson’s disease – a pilot study
Objective: The aim of our study was to measure total salivary α-synuclein in Parkinson´s disease (PD) patients to assess its potential as a biomarker of…
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 60
- Next Page »